Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice

Nature Medicine

Volumn 20, Issue 6, 2014, Pages 676-681

  Qin, Hong ^a   Lerman, Beatrisa ^a,b   Sakamaki, Ippei ^a   Wei, Guowei ^a   Cha, Soungchul C ^a   Rao, Sheetal S ^a   Qian, Jianfei ^a   Hailemichael, Yared ^a   Nurieva, Roza ^a   Dwyer, Karen C ^a   Roth, Johannes ^c   Yi, Qing ^a   Overwijk, Willem W ^a   Kwak, Larry W ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE MARKER; HYBRID PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY GR 1; PEPTIBODY; PEPTIBODY G3; PEPTIBODY H6; PEPTIDE DERIVATIVE; PROTEIN S 100; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; GRANULOCYTE; IMMUNE EVASION; IMMUNOCOMPETENT CELL; IMMUNOPRECIPITATION; IN VIVO STUDY; MONOCYTE; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN FAMILY; SPLEEN; SUPPRESSOR CELL; TUMOR MICROENVIRONMENT; TUMOR MODEL;

MUS;

ANIMALS; IMMUNOPRECIPITATION; MICE; MYELOID CELLS; NEOPLASMS; PEPTIDE LIBRARY; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; S100 PROTEINS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84902129552     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.3560     Document Type: Article

References (16)

1. Cheever, M.A. & Higano, C.S. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 17, 3520-3526 (2011).
2. Schwartzentruber, D.J. et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N. Engl. J. Med. 364, 2119-2127 (2011).
3. Schuster, S.J. et al. Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J. Clin. Oncol. 29, 2787-2794 (2011).
4. Marigo, I., Dolcetti, L., Serafini, P., Zanovello, P. & Bronte, V. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol. Rev. 222, 162-179 (2008). (Pubitemid 351430364)
5. Gabrilovich, D.I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9, 162-174 (2009).
6. Peranzoni, E. et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr. Opin. Immunol. 22, 238-244 (2010).
7. Bronte, V. & Zanovello, P. Regulation of immune responses by l-arginine metabolism. Nat. Rev. Immunol. 5, 641-654 (2005). (Pubitemid 41113195)
8. Rodriguez, P.C. et al. Regulation of T cell receptor CD3ς chain expression by l-arginine. J. Biol. Chem. 277, 21123-21129 (2002). (Pubitemid 34952247)
9. Ochoa, A.C., Zea, A.H., Hernandez, C. & Rodriguez, P.C. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin. Cancer Res. 13, 721s-726s (2007).
10. Ugel, S. et al. Therapeutic targeting of myeloid-derived suppressor cells. Curr. Opin. Pharmacol. 9, 470-481 (2009).
11. Vogl, T. et al. MRP8 and MRP14 control microtubule reorganization during transendothelial migration of phagocytes. Blood 104, 4260-4268 (2004). (Pubitemid 39620181)
12. Cheng, P. et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J. Exp. Med. 205, 2235-2249 (2008).
13. Sinha, P. et al. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J. Immunol. 181, 4666-4675 (2008).
14. Ichikawa, M., Williams, R., Wang, L., Vogl, T. & Srikrishna, G. S100A8/A9 activate key genes and pathways in colon tumor progression. Mol. Cancer Res. 9, 133-148 (2011).
15. Källberg, E. et al. S100A9 interaction with TLR4 promotes tumor growth. PLoS ONE 7, e34207 (2012).
16. Zhao, F. et al. S100A9 a new marker for monocytic human myeloid-derived suppressor cells. Immunology 136, 176-183 (2012).